Alpha Cognition CEO to Join CNS Small Cap Panel at B. Riley Summit
Event summary
- Alpha Cognition CEO Michael McFadden to participate in Late-Stage & Commercial CNS Small Cap panel on July 16, 2026.
- Panel discussion scheduled for 3:10 p.m. to 3:50 p.m. ET at B. Riley Securities Mind, Muscle & Vision Summit in Boston.
- No live webcast of the panel; 1x1 meetings available through institutional representatives.
- Alpha Cognition focuses on neurodegenerative disorders with ZUNVEYL for Alzheimer’s and benzgalantamine pipeline.
The big picture
Alpha Cognition’s participation in the B. Riley Summit underscores its push to engage institutional investors amid a competitive landscape for neurodegenerative treatments. The company’s focus on ZUNVEYL and benzgalantamine positions it within a niche but growing segment of CNS therapies, where differentiation through receptor binding could be key.
What we're watching
- Market Adoption
- How Alpha Cognition will leverage the summit to accelerate ZUNVEYL’s commercialization and market penetration.
- Pipeline Progress
- Whether benzgalantamine combination therapies can advance through clinical development as planned.
- Investor Sentiment
- The pace at which investor interest in CNS small-cap stocks may shift post-summit discussions.
Related topics